Stock 2696 SHANGHAI HENLIUS BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
16.34 HKD +4.08% Intraday chart for Shanghai Henlius Biotech, Inc. +12.23% +17.55%
Apr. 24 Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China MT
Apr. 23 Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China CI

Business Summary

Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.

Number of employees: 3,637

Sales per Business

HKD in Million2022Weight2023Weight Delta
Biopharmaceutical
100.0 %
3,738 100.0 % 5,961 100.0 % +59.47%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
89.2 %
3,303 88.4 % 5,316 89.2 % +60.92%
North America
5.8 %
169 4.5 % 348 5.8 % +106.21%
Asia Pacific (excluding China)
3.6 %
208 5.6 % 214 3.6 % +3.00%
Europe
1.0 %
58 1.6 % 62 1.0 % +6.83%
South America
0.4 %
-- 21 0.4 % -

Managers

Managers TitleAgeSince
Wei Dong Jiang FOU
 Founder - 09-11-30
Jun Zhu CEO
 Chief Executive Officer 46 21-11-29
Wei Huang PSD
 President 56 20-09-30
Wen Jie Zhang CHM
 Chairman 57 19-02-28
Simon Hsu CTO
 Chief Tech/Sci/R&D Officer - -
Miao Jie Chen CMP
 Compliance Officer 41 -
Ye Xing Yuan BRD
 Director/Board Member 39 22-12-31
Jin Li LAW
 General Counsel - 21-09-12
Jing Li PRN
 Corporate Officer/Principal - -
Ping Cao PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Qi Yu Chen BRD
 Director/Board Member 52 13-01-14
Tak Young So BRD
 Director/Board Member 54 19-09-01
Xiao Hui Guan BRD
 Director/Board Member 53 18-12-23
Yi Fang Wu BRD
 Director/Board Member 54 15-06-11
De Yong Wen BRD
 Director/Board Member 52 22-07-27
Lik Yuen Chan BRD
 Director/Board Member 55 -
Guo Ping Zhao BRD
 Director/Board Member 75 19-09-01
Rong Li Feng CHM
 Chairman 49 20-04-20
De Li Kong BRD
 Director/Board Member 50 16-07-31
Xing Li Wang BRD
 Director/Board Member 61 23-08-27

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 380,066,312 0 0 15.03 %
Stock B 1 163,428,541 81,687,447 ( 49.98 %) 0

Shareholders

NameEquities%Valuation
Henlius Biopharmaceuticals, Inc. /Ky/
26.77 %
43,756,960 26.77 % 76 M $
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
21.74 %
35,523,439 21.74 % 62 M $
Qatar Holding LLC
6.958 %
11,370,960 6.958 % 20 M $
Qatar Investment Authority (Investment Management)
1.739 %
2,842,740 1.739 % 5 M $
Shi Gao Liu
1.475 %
2,410,695 1.475 % 4 M $
Wei Dong Jiang
0.4411 %
720,955 0.4411 % 1 M $
Jun Zhu
0.0306 %
50,000 0.0306 % 87 013 $
Baron Capital Management, Inc.
0.000617 %
1,009 0.000617 % 1 756 $
NameEquities%Valuation
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
80.00 %
291,365,387 80.00 % 507 M $
Jun Zhu
0.0454 %
165,450 0.0454 % 287 924 $
NameEquities%Valuation
Henlink, Inc.
9.715 %
15,876,694 9.715 % 28 M $

Company contact information

Shanghai Henlius Biotech, Inc.

Innov Tower 1801 Hongmei Road, Xuhui District

200233, Shanghai

+

http://www.henlius.com
address Shanghai Henlius Biotech, Inc.(2696)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Shanghai Henlius Biotech, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.12 CNY
Average target price
16.39 CNY
Spread / Average Target
+8.41%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SHANGHAI HENLIUS BIOTECH, INC. Stock Shanghai Henlius Biotech, Inc.
+17.55% 1.09B
CSL LIMITED Stock CSL Limited
-2.86% 87.31B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.63% 40.86B
BIOGEN INC. Stock Biogen Inc.
-22.90% 29.36B
UCB Stock UCB
+58.56% 24.49B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.67% 17.31B
INCYTE CORPORATION Stock Incyte Corporation
-19.16% 11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-15.61% 11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.02% 11.26B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.17% 8.31B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. Company Shanghai Henlius Biotech, Inc.